The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice

Abstract

Cerebral amyloid angiopathy (CAA) has never been more relevant. The last 5 years have seen a rapid increase in publications and research in the field, with the development of new biomarkers for the disease, thanks to advances in MRI, amyloid positron emission tomography and cerebrospinal fluid biomarker analysis. The inadvertent development of CAA-like pathology in patients treated with amyloid-beta immunotherapy for Alzheimer's disease has highlighted the importance of establishing how and why CAA develops; without this information, the use of these treatments may be unnecessarily restricted. Our understanding of the clinical and radiological spectrum of CAA has continued to evolve, and there are new insights into the independent impact that CAA has on cognition in the context of ageing and intracerebral haemorrhage, as well as in Alzheimer's and other dementias. While the association between CAA and lobar intracerebral haemorrhage (with its high recurrence risk) is now well recognised, a number of management dilemmas remain, particularly when considering the use of antithrombotics, anticoagulants and statins. The Boston criteria for CAA, in use in one form or another for the last 20 years, are now being reviewed to reflect these new wide-ranging clinical and radiological findings. This review aims to provide a 5-year update on these recent advances, as well as a look towards future directions for CAA research and clinical practice.

References 174

1. 1.

   Pantoni L Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.

   Not in our library10.1016/s1474-4422(10)70104-6

2. 2.

   Smith EE, Eichler F Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol 2006;63:148–51.

   Not in our library10.1001/archneur.63.1.148

3. 3.

   Charidimou A, Gang Q, Werring DJ Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012;83:124–37.

   Not in our library10.1136/jnnp-2011-301308

4. 4.

   Charidimou A, Fox Z, Werring DJ, et al Mapping the landscape of cerebral amyloid angiopathy research: an informetric analysis perspective. J Neurol Neurosurg Psychiatry 2016;87:252–9.

   Not in our library10.1136/jnnp-2015-310690

5. 5.

   Sperling R, Salloway S, Brooks DJ, et al Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–9.

   Not in our library10.1016/s1474-4422(12)70015-7

6. 6.

   Knudsen KA, Rosand J, Karluk D, et al Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537–9.

   Not in our library10.1212/wnl.56.4.537

7. 7.

   Linn J, Halpin A, Demaerel P, et al Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74:1346–50.

   Not in our library10.1212/wnl.0b013e3181dad605

8. 8.

   Levy E, Carman MD, Fernandez-Madrid IJ, et al Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124–6.

   Not in our library10.1126/science.2111584

9. 9.

   Bornebroek M, Haan J, Maat-Schieman ML, et al Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): I--A review of clinical, radiologic and genetic aspects. Brain Pathol 1996;6:111–4.

   Not in our library10.1111/j.1750-3639.1996.tb00793.x

10. 10.

    Bornebroek M, De Jonghe C, Haan J, et al Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis 2003;14:619–23.

    Not in our library10.1016/j.nbd.2003.08.019

11. 11.

    van den Boom R, Bornebroek M, Behloul F, et al Microbleeds in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurology 2005;64:1288–9.

    Not in our library10.1212/01.wnl.0000156946.44593.24

12. 12.

    van Rooden S, van der Grond J, van den Boom R, et al Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population. Stroke 2009;40:3022–7.

    Not in our library10.1161/strokeaha.109.554378

13. 13.

    van Rooden S, van Opstal AM, Labadie G, et al Early magnetic resonance imaging and cognitive markers of hereditary cerebral amyloid angiopathy. Stroke 2016;47:3041–4.

    Not in our library10.1161/strokeaha.116.014418

14. 14.

    Fotiadis P, van Rooden S, van der Grond J, et al Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol 2016;15:811–9.

    Not in our library10.1016/s1474-4422(16)30030-8

15. 15.

    Dumas A, Dierksen GA, Gurol ME, et al Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol 2012;72:76–81.

    Not in our library10.1002/ana.23566

16. 16.

    van Opstal AM, van Rooden S, van Harten T, et al Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study. Lancet Neurol 2017;16:115–22.

    Not in our library10.1016/s1474-4422(16)30346-5

17. 17.

    van Etten ES, Gurol ME, van der Grond J, et al Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016;87:1482–7.

    Not in our library10.1212/wnl.0000000000003181

18. 18.

    van Etten ES, Verbeek MM, van der Grond J, et al β-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology 2017;88:169–76.

    Not in our library10.1212/wnl.0000000000003486

19. 19.

    Charidimou A, Meegahage R, Fox Z, et al Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiat 2013;84:624–9.

    Not in our library10.1136/jnnp-2012-304434

20. 20.

    Charidimou A, Jäger RH, Peeters A, et al White matter perivascular spaces are related to cortical superficial siderosis in cerebral amyloid angiopathy. Stroke 2014;45:2930–5.

    Not in our library10.1161/strokeaha.114.005568

21. 21.

    Charidimou A, Jaunmuktane Z, Baron JC, et al White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology 2014;82:57–62.

    Not in our library10.1212/01.wnl.0000438225.02729.04

22. 22.

    Koo HW, Jo KI, Yeon JY, et al Clinical features of high-degree centrum semiovale-perivascular spaces in cerebral amyloid angiopathy. J Neurol Sci 2016;367:89–94.

    Not in our library10.1016/j.jns.2016.05.040

23. 23.

    Charidimou A, Hong YT, Jäger HR, et al White matter perivascular spaces on magnetic resonance imaging: marker of cerebrovascular amyloid burden? Stroke 2015;46:1707–9.

    Not in our library10.1161/strokeaha.115.009090

24. 24.
    Enlarged Perivascular Spaces and Cerebral Small Vessel Disease · 2013

    No notice
25. 25.

    Peca S, McCreary CR, Donaldson E, et al Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013;81:1659–65.

    Not in our library10.1212/01.wnl.0000435291.49598.54

26. 26.

    Switzer AR, McCreary C, Batool S, et al Longitudinal decrease in blood oxygenation level dependent response in cerebral amyloid angiopathy. Neuroimage Clin 2016;11:461–7.

    Not in our library10.1016/j.nicl.2016.02.020

27. 27.

    Gurol ME, Dierksen G, Betensky R, et al Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012;79:320–6.

    Not in our library10.1212/wnl.0b013e31826043a9

28. 28.

    Baron JC, Farid K, Dolan E, et al Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 2014;34:753–8.

    Not in our library10.1038/jcbfm.2014.43

29. 29.

    Farid K, Hong YT, Aigbirhio FI, et al Early-Phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value? PLoS One 2015;10:e0139926

    Not in our library10.1371/journal.pone.0139926

30. 30.

    Gurol ME, Becker JA, Fotiadis P, et al Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study. Neurology 2016;87:2043–9.

    Not in our library10.1212/wnl.0000000000003197

31. 31.

    Greenberg SM, Al-Shahi Salman R, Biessels GJ, et al Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 2014;13:419–28.

    Not in our library10.1016/s1474-4422(14)70003-1

32. 32.

    Lummel N, Wollenweber FA, Demaerel P, et al Clinical spectrum, underlying etiologies and radiological characteristics of cortical superficial siderosis. J Neurol 2015;262:1455–62.

    Not in our library10.1007/s00415-015-7736-1

33. 33.

    Linn J, Wollenweber FA, Lummel N, et al Superficial siderosis is a warning sign for future intracranial hemorrhage. J Neurol 2013;260:176–81.

    Not in our library10.1007/s00415-012-6610-7

34. 34.

    Charidimou A, Peeters AP, Jäger R, et al Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology 2013;81:1666–73.

    Not in our library10.1212/01.wnl.0000435298.80023.7a

35. 35.

    Wilson D, Hostettler IC, Ambler G, et al Convexity subarachnoid haemorrhage has a high risk of intracerebral haemorrhage in suspected cerebral amyloid angiopathy. J Neurol 2017;264

    Not in our library10.1007/s00415-017-8398-y

36. 36.

    Roongpiboonsopit D, Charidimou A, William CM, et al Cortical superficial siderosis predicts early recurrent lobar hemorrhage. Neurology 2016;87:1863–70.

    Not in our library10.1212/wnl.0000000000003281

37. 37.

    Na HK, Park JH, Kim JH, et al Cortical superficial siderosis: a marker of vascular amyloid in patients with cognitive impairment. Neurology 2015;84:849–55.

    Not in our library10.1212/wnl.0000000000001288

38. 38.

    Zonneveld HI, Goos JD, Wattjes MP, et al Prevalence of cortical superficial siderosis in a memory clinic population. Neurology 2014;82:698–704.

    Not in our library10.1212/wnl.0000000000000150

39. 39.

    Wollenweber FA, Buerger K, Mueller C, et al Prevalence of cortical superficial siderosis in patients with cognitive impairment. J Neurol 2014;261:277–82.

    Not in our library10.1007/s00415-013-7181-y

40. 40.

    Inoue Y, Nakajima M, Uetani H, et al Diagnostic significance of cortical superficial siderosis for Alzheimer Disease in patients with cognitive impairment. Am J Neuroradiol 2016;37:223–7.

    Not in our library10.3174/ajnr.a4496

Cited by papers we hold 3

• Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease · 2023
  No notice
• sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy · 2022
  Not checked
• Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.